Candel Therapeutics, INC. (CADL) — 8-K Filings

All 8-K filings from Candel Therapeutics, INC.. Browse 27 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (27)

Candel Therapeutics Files 8-K — Dec 5, 2025 Risk: low
Candel Therapeutics, Inc. filed an 8-K on December 5, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
Candel Therapeutics Files 8-K with Material Agreements and Financial Updates — Oct 14, 2025 Risk: medium
On October 14, 2025, Candel Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, repor
Candel Therapeutics Enters Material Definitive Agreement — Aug 21, 2025 Risk: medium
Candel Therapeutics, Inc. announced on August 18, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of t
Candel Therapeutics Files 8-K: Material Agreement — Jun 24, 2025 Risk: medium
On June 23, 2025, Candel Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statem
Candel Therapeutics Files 8-K on Officer/Director Changes — Jun 23, 2025 Risk: medium
Candel Therapeutics, Inc. filed an 8-K on June 23, 2025, reporting events as of June 20, 2025. The filing indicates changes related to the departure of director
Candel Therapeutics Reports on Shareholder Vote Outcomes — Jun 18, 2025 Risk: low
Candel Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of its security holders on June 17, 2025. The filing details t
Candel Therapeutics Reports Officer/Director Changes — Jun 6, 2025 Risk: medium
Candel Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting events as of June 4, 2025. The filing indicates changes related to the departure of directors
Candel Therapeutics Files 8-K Report — May 28, 2025 Risk: low
On May 28, 2025, Candel Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a R
Candel Therapeutics Files 8-K — May 22, 2025 Risk: low
Candel Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing d
Candel Therapeutics Files 8-K — Apr 23, 2025 Risk: low
Candel Therapeutics, Inc. filed an 8-K on April 23, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
Candel Therapeutics Files 8-K — Mar 27, 2025 Risk: low
Candel Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting events as of March 26, 2025. The filing includes information related to Regulation FD Disclo
Candel Therapeutics Files 8-K — Feb 25, 2025 Risk: low
Candel Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures,
Candel Therapeutics Files 8-K on Financials and Operations — Jan 13, 2025 Risk: medium
Candel Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures
Candel Therapeutics Files 8-K: Material Agreement and Other Events — Dec 13, 2024 Risk: medium
On December 12, 2024, Candel Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial stateme
Candel Therapeutics Files 8-K — Dec 11, 2024 Risk: medium
Candel Therapeutics, Inc. filed an 8-K on December 11, 2024, to report on various events. The filing includes information related to Regulation FD Disclosure, O
Candel Therapeutics Files 8-K — Oct 28, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting on financial statements and exhibits, along with other events and a Regulation FD disclosu
Candel Therapeutics Reports Shareholder Vote — Jun 28, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on June 28, 2024, reporting on a matter submitted to a vote of its security holders on June 26, 2024. The filing does not
Candel Therapeutics Files 8-K with Corporate Updates — May 30, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on May 29, 2024, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhi
Candel Therapeutics Files 8-K — May 23, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on May 23, 2024, to report on other events and financial statements. The filing does not contain specific details about n
Candel Therapeutics Files 8-K — Apr 25, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on April 25, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
Candel Therapeutics Partners with Bristol Myers Squibb for Cancer Trial — Apr 11, 2024 Risk: medium
Candel Therapeutics, Inc. announced on April 11, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration wil
Candel Therapeutics Files 8-K — Apr 9, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on April 9, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, othe
Candel Therapeutics Partners with Bristol Myers Squibb for Melanoma Trial — Apr 4, 2024 Risk: medium
Candel Therapeutics, Inc. announced on April 4, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will
Candel Therapeutics Files 8-K for Regulatory and Financial Updates — Mar 6, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on March 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
Candel Therapeutics Files 8-K on Feb 13, Details Undisclosed — Feb 13, 2024 Risk: low
Candel Therapeutics, Inc. filed an 8-K on February 13, 2024, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The fil
Candel Therapeutics Amends Officer Compensation on Jan 12 — Jan 12, 2024
Candel Therapeutics, Inc. (CADL) announced on January 12, 2024, that it has entered into new compensatory arrangements with certain officers. This 8-K filing, u
Candel Therapeutics Confirms Emerging Growth Status in 8-K Filing — Jan 3, 2024
Candel Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an "Other Event" that occurred on December 28, 2023. This filing indicates that the company

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX